Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab versus rituximab induction in ABO-incompatible kidney transplantation
NL-OMON28980Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of alemtuzumab and rituximab in end-stage kidney disease (ESKD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Biopsy-proven acute rejection within 3 months. Started Apr 2015; status: recruiting.
02
Drugs
alemtuzumabrituximab
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON28980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28980.